In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ParAllele BioScience Inc.

Division of Thermo Fisher Scientific Inc.
www.p-gene.com

Latest From ParAllele BioScience Inc.

Versant's Big Bets on Small Companies

For a firm with a large amount of capital under management, Versant Ventures may be somewhat unusual. Although it typically invests between $8-$12 million per company, it will also invest as little as $50,000 in a seed stage operation.
BioPharmaceutical Medical Device

Deal Statistics Quarterly, Q2 2005

In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
BioPharmaceutical Medical Device

Making a New, Big Splash in the Sequencing Market

If one of the first ingredients of a successful tool company deal is to invest as little capital as possible, what then to make of the hefty $27 million raised by Helicos, a developer of high-throughput sequencing systems? The company that successfully integrates the technologies needed for single-molecule sequencing could find a fast and rewarding exit, and neither their investors nor management reject the possibility of a buy-out even before their products hit the market in a few years.
Business Strategies Business Strategies

Roche's Challenging Biomarker Strategy

Large pharma companies are increasingly interested in using biomarkers to shorten R&D timelines and reduce the risks of developing new drugs. Roche says its recently formalized biomarker program benefits from the firm's unique expertise in diagnostics. But like its competitors embarked on siimilar efforts, Roche won't know the value of this complex undertaking for years.
Business Strategies Leadership
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Bioinformatics
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Thermo Fisher Scientific Inc.
  • Senior Management
  • Nicholas J Naclerio, PhD, Pres.
    Thomas Willis, PhD, CSO
  • Contact Info
  • ParAllele BioScience Inc.
    Phone: (650) 583-5833
    384 Oyster Point Blvd., Ste. 8
    S. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register